TY - JOUR
T1 - Pseudomonas pneumonia. A retrospective study of 36 cases
AU - Pennington, James E.
AU - Reynolds, Herbert Y.
AU - Carbone, Paul P.
N1 - Funding Information:
From the Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, and the Division of Medical Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014. Requests for reprints should be addressed to Dr. James E. Pennington, National Institutes of Health, Building 10, Room 11 B-18, Bethesda, Maryland 20014. Manuscript accepted March 5, 1973.
PY - 1973/8
Y1 - 1973/8
N2 - The clinical course in 36 cases of Pseudomonas pneumonia collected over a 15 year period (1956 to 1970) at the Clinical Center of the National Institutes of Health were reviewed to identify factors which increased the risk of infection and affected prognosis. In all cases, the patients had a serious underlying disease which predisposed to infection, and the majority had neoplastic diseases, particularly acute leukemia; cardiac or pulmonary diseases were less frequent. Pseudomonas related mortality was 81 per cent and was not influenced by type of antibiotic therapy or by the year of occurrence. Many patients were neutropenic, usually subsequent to cytotoxic chemotherapy, and frequently had been treated with steroids or antibiotics just prior to the development of pneumonia. Adequate numbers of circulating granulocytes were essential to survival. No patient with a positive blood culture survived. Possibilities for new means of prevention and treatment of Pseudomonas pneumonia are discussed.
AB - The clinical course in 36 cases of Pseudomonas pneumonia collected over a 15 year period (1956 to 1970) at the Clinical Center of the National Institutes of Health were reviewed to identify factors which increased the risk of infection and affected prognosis. In all cases, the patients had a serious underlying disease which predisposed to infection, and the majority had neoplastic diseases, particularly acute leukemia; cardiac or pulmonary diseases were less frequent. Pseudomonas related mortality was 81 per cent and was not influenced by type of antibiotic therapy or by the year of occurrence. Many patients were neutropenic, usually subsequent to cytotoxic chemotherapy, and frequently had been treated with steroids or antibiotics just prior to the development of pneumonia. Adequate numbers of circulating granulocytes were essential to survival. No patient with a positive blood culture survived. Possibilities for new means of prevention and treatment of Pseudomonas pneumonia are discussed.
UR - http://www.scopus.com/inward/record.url?scp=0015786165&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015786165&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(73)90163-0
DO - 10.1016/0002-9343(73)90163-0
M3 - Article
C2 - 4198683
AN - SCOPUS:0015786165
SN - 0002-9343
VL - 55
SP - 155
EP - 160
JO - The American journal of medicine
JF - The American journal of medicine
IS - 2
ER -